TPN-101, 100 mg/day ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 5 | 進行性核上性麻痺 | 1 |
5. 進行性核上性麻痺
臨床試験数 : 95 / 薬物数 : 119 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04993768 (ClinicalTrials.gov) | October 15, 2021 | 19/7/2021 | A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) | A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy | Drug: TPN-101, 100 mg/day;Drug: TPN-101, 200 mg/day;Drug: TPN-101, 400 mg/day;Drug: Placebo | Transposon Therapeutics, Inc. | NULL | Recruiting | 41 Years | 86 Years | All | 40 | Phase 2 | United States |